Katsuomi Iwakura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katsuomi Iwakura has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
Kenshi Fujii
Cardiovascular Center, Sakurabashi Watanabe Advanced Healthcare Hospital
28 shared publicationsYasushi Koyama
Division of Cardiology, Sakurabashi Watanabe Advanced Healthcare Hospital, OSAKA, Japan
23 shared publicationsAtsunori Okamura
Division of Cardiology, Sakurabashi Watanabe Advanced Healthcare Hospital, OSAKA, Japan
16 shared publications- Koichi Inoue
Cardiovascular Division National Hospital Organization Osaka National Hospital Osaka Japan
12 shared publications - Masato Okada
Cardiovascular Center, Sakurabashi Watanabe Advanced Healthcare Hospital Osaka Japan
12 shared publications Motoo Date
Department of Cardiology, Sakurabashi-Watanabe Hospital, 2-4-32, Umeda, Kita-ku, Osaka, Japan
12 shared publications
Latest Publications
- 3 September 2026
- Published by Elsevier in Journal of the American Society of Echocardiography
Prognostic Implications of the 2025 American Society of Echocardiography Guidelines for the Evaluation of Left Ventricular Diastolic Function in Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation
- 3 September 2026
- Published by Elsevier in Journal of the American Society of Echocardiography
Prognostic Implications of the 2025 American Society of Echocardiography Guidelines for the Evaluation of Left Ventricular Diastolic Function in Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e046708
Sex Differences in Characteristics and Outcomes Among Patients With Hypertrophic Cardiomyopathy: Insights From the REVEAL‐HCM Study
Background: Female sex has been associated with poor prognosis in hypertrophic cardiomyopathy (HCM), but the factors contributing to this disparity remain insufficiently defined. We aimed to clarify sex differences in clinical characteristics and factors associated with cardiovascular death in Japan. Methods: This multicenter, retrospective observational study of HCM was conducted between January 1, 2006, and December 31, 2018 (REVEAL‐HCM study [Multicenter Registry to Evaluate Risk Factors for Disease Progression, Sudden Cardiac Death and Adverse Clinical Outcomes in Japanese Patients With Hypertrophic Cardiomyopathy]; UMIN000046932). Patients aged ≥16 years with HCM were enrolled. Baseline characteristics and clinical outcomes including cardiovascular death were assessed. Univariable and multivariable Cox proportional hazards models were used to identify factors associated with cardiovascular death. Results: Of 3247 patients (median age, 67 years; 43% women), women were older and more symptomatic at presentation (52% New York Heart Association class II–IV versus 35% in men). Cardiovascular death was more common in women (hazard ratio [HR], 1.37 [95% CI, 1.02–1.82]; P =0.03). In multivariable analysis, older age (per 1‐year increase; HR, 1.04 [95% CI, 1.02–1.06]), advanced New York Heart Association class (HR, 1.99 [95% CI, 1.40–2.82]), history of atrial fibrillation (HR, 1.55 [95% CI, 1.10–2.18]), greater maximal wall thickness indexed to body surface area (per 1‐mm/m 2 increase; HR, 1.12 [95% CI, 1.06–1.20]), and apical HCM (HR, 0.53 [95% CI, 0.32–0.88]) were independently associated with cardiovascular death, attenuating the HR for female sex. Conclusions: Sex differences in clinical characteristics and outcomes were observed. The excess cardiovascular death in women with HCM was largely explained by older age, more advanced symptoms, greater indexed wall thickness, and sex‐specific differences in both the prevalence and prognostic impact of apical HCM.
- 7 July 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (13) , e046708
Sex Differences in Characteristics and Outcomes Among Patients With Hypertrophic Cardiomyopathy: Insights From the REVEAL‐HCM Study
Background: Female sex has been associated with poor prognosis in hypertrophic cardiomyopathy (HCM), but the factors contributing to this disparity remain insufficiently defined. We aimed to clarify sex differences in clinical characteristics and factors associated with cardiovascular death in Japan. Methods: This multicenter, retrospective observational study of HCM was conducted between January 1, 2006, and December 31, 2018 (REVEAL‐HCM study [Multicenter Registry to Evaluate Risk Factors for Disease Progression, Sudden Cardiac Death and Adverse Clinical Outcomes in Japanese Patients With Hypertrophic Cardiomyopathy]; UMIN000046932). Patients aged ≥16 years with HCM were enrolled. Baseline characteristics and clinical outcomes including cardiovascular death were assessed. Univariable and multivariable Cox proportional hazards models were used to identify factors associated with cardiovascular death. Results: Of 3247 patients (median age, 67 years; 43% women), women were older and more symptomatic at presentation (52% New York Heart Association class II–IV versus 35% in men). Cardiovascular death was more common in women (hazard ratio [HR], 1.37 [95% CI, 1.02–1.82]; P =0.03). In multivariable analysis, older age (per 1‐year increase; HR, 1.04 [95% CI, 1.02–1.06]), advanced New York Heart Association class (HR, 1.99 [95% CI, 1.40–2.82]), history of atrial fibrillation (HR, 1.55 [95% CI, 1.10–2.18]), greater maximal wall thickness indexed to body surface area (per 1‐mm/m 2 increase; HR, 1.12 [95% CI, 1.06–1.20]), and apical HCM (HR, 0.53 [95% CI, 0.32–0.88]) were independently associated with cardiovascular death, attenuating the HR for female sex. Conclusions: Sex differences in clinical characteristics and outcomes were observed. The excess cardiovascular death in women with HCM was largely explained by older age, more advanced symptoms, greater indexed wall thickness, and sex‐specific differences in both the prevalence and prognostic impact of apical HCM.
- Open Access
The Risk Estimation by the PREVENT equations and Clinical Outcome in Patients with Heart Failure with Preserved Ejection Fraction
Background: The PREVENT (Predicting Risk of CVD EVENTs) equations estimate the risk of incident cardiovascular disease (CVD) in primary prevention patients. We hypothesized that risk factors incorporated in the equations may be relevant to prognosis in heart failure (HF) and investigated the association between estimated CVD risk and clinical outcomes in patients with preserved ejection fraction (HFpEF). Methods: We estimated the 10-year CVD risk using the PREVENT equations in 278 patients hospitalized for acutely decompensated HFpEF (median 75 years, 51.4% male). We divided them into four groups according to the quartiles of estimated CVD risk and followed them to observe major adverse cardiovascular events (MACE), a composite of all-cause death, HF hospitalization, and stroke. Results: MACE occurred in 125 patients (45.0%) over a median follow-up of 1,050 days. The estimated CVD risk classification was an independent predictor for MACE (p=0.02) in the multivariable Cox proportional hazard model. There was a difference in MACE-free survival across the four quartile groups (p<0.001 by log-rank test), and the lowest CVD risk group had significantly lower MACE incidence than other groups. The estimated CVD risk provided incremental prognostic value beyond N-terminal pro-B type natriuretic peptide (C-index: 0.626 vs, P=0.009). The predictive value of the estimated CVD risk for MACE at 1 year was comparable to that of the MAGGIC score (AUC 0.676 vs. 0.639, p=0.42). Conclusions: The 10-year CVD risk estimated by the PREVENT equations had a moderate predictive value for MACE in patients hospitalized for HFpEF.
Open AccessThe Risk Estimation by the PREVENT equations and Clinical Outcome in Patients with Heart Failure with Preserved Ejection Fraction
Background: The PREVENT (Predicting Risk of CVD EVENTs) equations estimate the risk of incident cardiovascular disease (CVD) in primary prevention patients. We hypothesized that risk factors incorporated in the equations may be relevant to prognosis in heart failure (HF) and investigated the association between estimated CVD risk and clinical outcomes in patients with preserved ejection fraction (HFpEF). Methods: We estimated the 10-year CVD risk using the PREVENT equations in 278 patients hospitalized for acutely decompensated HFpEF (median 75 years, 51.4% male). We divided them into four groups according to the quartiles of estimated CVD risk and followed them to observe major adverse cardiovascular events (MACE), a composite of all-cause death, HF hospitalization, and stroke. Results: MACE occurred in 125 patients (45.0%) over a median follow-up of 1,050 days. The estimated CVD risk classification was an independent predictor for MACE (p=0.02) in the multivariable Cox proportional hazard model. There was a difference in MACE-free survival across the four quartile groups (p<0.001 by log-rank test), and the lowest CVD risk group had significantly lower MACE incidence than other groups. The estimated CVD risk provided incremental prognostic value beyond N-terminal pro-B type natriuretic peptide (C-index: 0.626 vs, P=0.009). The predictive value of the estimated CVD risk for MACE at 1 year was comparable to that of the MAGGIC score (AUC 0.676 vs. 0.639, p=0.42). Conclusions: The 10-year CVD risk estimated by the PREVENT equations had a moderate predictive value for MACE in patients hospitalized for HFpEF.
- Open Access
- 21 May 2026
- Published by Elsevier in JACC: Asia
Triglyceride-Glucose Index and Clinical Outcome in Patients With Heart Failure With Preserved Ejection Fraction
- 21 May 2026
- Published by Elsevier in JACC: Asia
Open AccessTriglyceride-Glucose Index and Clinical Outcome in Patients With Heart Failure With Preserved Ejection Fraction
- Open Access
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e044945
Clinical Implications of Left Atrial and Ventricular Reverse Remodeling After Atrial Fibrillation Ablation in Patients With Systolic Dysfunction
Background: Catheter ablation of atrial fibrillation (AF) is an effective treatment to achieve left atrial (LA) and left ventricular (LV) reverse remodeling in patients with systolic dysfunction. However, the relationship between LA and LV reverse remodeling (LARR and LVRR) and their clinical implications remains unclear. Methods: Among 5287 consecutive patients undergoing first‐time AF ablation, 620 with baseline LV ejection fraction P P <0.001), whereas LARR−/LVRR− (HR, 6.73 [95% CI, 3.48–13.0]) and LARR+/LVRR− (HR, 4.58 [95% CI, 1.86–11.3]) were associated with the composite end point. Conclusions: LARR and LVRR were moderately correlated after AF ablation in patients with systolic dysfunction. Their combined assessment delineated distinct postablation trajectories and may improve individual risk stratification.
- 17 February 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (4) , e044945
Open AccessClinical Implications of Left Atrial and Ventricular Reverse Remodeling After Atrial Fibrillation Ablation in Patients With Systolic Dysfunction
Background: Catheter ablation of atrial fibrillation (AF) is an effective treatment to achieve left atrial (LA) and left ventricular (LV) reverse remodeling in patients with systolic dysfunction. However, the relationship between LA and LV reverse remodeling (LARR and LVRR) and their clinical implications remains unclear. Methods: Among 5287 consecutive patients undergoing first‐time AF ablation, 620 with baseline LV ejection fraction P P <0.001), whereas LARR−/LVRR− (HR, 6.73 [95% CI, 3.48–13.0]) and LARR+/LVRR− (HR, 4.58 [95% CI, 1.86–11.3]) were associated with the composite end point. Conclusions: LARR and LVRR were moderately correlated after AF ablation in patients with systolic dysfunction. Their combined assessment delineated distinct postablation trajectories and may improve individual risk stratification.
- Open Access
- 5 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (15) , e040646
Left Atrial Volumetric/Mechanical Coupling Index in Heart Failure With Preserved Ejection Fraction
Background: Left atrial (LA) dysfunction is common in heart failure with preserved ejection fraction (HFpEF). The LA volumetric/mechanical coupling index (LACI), calculated as the LA volume index divided by the late diastolic mitral annular velocity (a′), is a recently advocated parameter reflecting LA contractile function based on the atrial Frank–Starling mechanism. An elevated LACI signifies impaired mechanical performance despite greater atrial volume, indicating volumetric/mechanical uncoupling. Its associations with echocardiographic indices and prognostic significance in HFpEF remain unclear. Methods: This study included 562 patients from the PURSUIT‐HFpEF (Prospective Multicenter Observational Study of Patients With Heart Failure With Preserved Ejection Fraction) registry, a prospective multicenter registry for HFpEF. LACI was calculated and categorized into quartiles. Associations with echocardiographic indices and clinical outcomes were examined. Results: LA volume index and late diastolic mitral annular velocity were negatively correlated ( r =−0.26; P P =0.001). After multivariable adjustment, LACI remained a significant predictor of cardiovascular outcomes (hazard ratio, 1.18 per quartile increase [95% CI, 1.00–1.38]; P =0.045). Conclusions: In patients with HFpEF, LA mechanical activity decreased with LA enlargement, suggesting volumetric/mechanical uncoupling inherent in this cohort. LACI may serve as a clinically relevant index for risk stratification of cardiovascular death or rehospitalization for heart failure in patients with HFpEF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: UMIN000021831.
- 5 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (15) , e040646
Open AccessLeft Atrial Volumetric/Mechanical Coupling Index in Heart Failure With Preserved Ejection Fraction
Background: Left atrial (LA) dysfunction is common in heart failure with preserved ejection fraction (HFpEF). The LA volumetric/mechanical coupling index (LACI), calculated as the LA volume index divided by the late diastolic mitral annular velocity (a′), is a recently advocated parameter reflecting LA contractile function based on the atrial Frank–Starling mechanism. An elevated LACI signifies impaired mechanical performance despite greater atrial volume, indicating volumetric/mechanical uncoupling. Its associations with echocardiographic indices and prognostic significance in HFpEF remain unclear. Methods: This study included 562 patients from the PURSUIT‐HFpEF (Prospective Multicenter Observational Study of Patients With Heart Failure With Preserved Ejection Fraction) registry, a prospective multicenter registry for HFpEF. LACI was calculated and categorized into quartiles. Associations with echocardiographic indices and clinical outcomes were examined. Results: LA volume index and late diastolic mitral annular velocity were negatively correlated ( r =−0.26; P P =0.001). After multivariable adjustment, LACI remained a significant predictor of cardiovascular outcomes (hazard ratio, 1.18 per quartile increase [95% CI, 1.00–1.38]; P =0.045). Conclusions: In patients with HFpEF, LA mechanical activity decreased with LA enlargement, suggesting volumetric/mechanical uncoupling inherent in this cohort. LACI may serve as a clinically relevant index for risk stratification of cardiovascular death or rehospitalization for heart failure in patients with HFpEF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: UMIN000021831.
- Open Access
- 20 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (10) , e038742
Impact of Long‐Term CPAP Adherence on Recurrence After Atrial Fibrillation Ablation in Patients With Severe Sleep Apnea
Background: Obstructive sleep apnea represents an arrhythmia recurrence risk following catheter ablation of atrial fibrillation (AF). Continuous positive airway pressure (CPAP) therapy may reduce recurrence, but individual adherence to CPAP varies, potentially leading to inconsistent results across studies. Methods and Results: We analyzed the impact of CPAP adherence on AF recurrence after catheter ablation in patients with severe obstructive sleep apnea (apnea‐hypopnea index ≥30). Of 1864 consecutive patients undergoing an index catheter ablation of AF, those with severe obstructive sleep apnea were enrolled in this study. Recurrence rates were compared between patients with and without long‐term CPAP adherence (>1‐year use). CPAP use was monitored via telemonitoring and outpatient follow‐ups. Among 466 patients, 157 (33.7%) adhered to CPAP long‐term, reducing apnea‐hypopnea index from 37.7±15.3 to 3.9±3.1 ( P P =0.0002). Even after adjusting for potential confounders, long‐term CPAP treatment was associated with a lower risk of very late recurrence (adjusted hazard ratio, 0.30 [95% CI, 0.14–0.57]). Conclusions: In patients with severe obstructive sleep apnea at baseline, AF recurrence rates within 1‐year postablation were similar regardless of CPAP adherence. However, long‐term CPAP therapy was associated with a reduced AF recurrence rate in the subsequent period.
- 20 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (10) , e038742
Open AccessImpact of Long‐Term CPAP Adherence on Recurrence After Atrial Fibrillation Ablation in Patients With Severe Sleep Apnea
Background: Obstructive sleep apnea represents an arrhythmia recurrence risk following catheter ablation of atrial fibrillation (AF). Continuous positive airway pressure (CPAP) therapy may reduce recurrence, but individual adherence to CPAP varies, potentially leading to inconsistent results across studies. Methods and Results: We analyzed the impact of CPAP adherence on AF recurrence after catheter ablation in patients with severe obstructive sleep apnea (apnea‐hypopnea index ≥30). Of 1864 consecutive patients undergoing an index catheter ablation of AF, those with severe obstructive sleep apnea were enrolled in this study. Recurrence rates were compared between patients with and without long‐term CPAP adherence (>1‐year use). CPAP use was monitored via telemonitoring and outpatient follow‐ups. Among 466 patients, 157 (33.7%) adhered to CPAP long‐term, reducing apnea‐hypopnea index from 37.7±15.3 to 3.9±3.1 ( P P =0.0002). Even after adjusting for potential confounders, long‐term CPAP treatment was associated with a lower risk of very late recurrence (adjusted hazard ratio, 0.30 [95% CI, 0.14–0.57]). Conclusions: In patients with severe obstructive sleep apnea at baseline, AF recurrence rates within 1‐year postablation were similar regardless of CPAP adherence. However, long‐term CPAP therapy was associated with a reduced AF recurrence rate in the subsequent period.
- Open Access
Association between Triglyceride-Glucose Index and Clinical Outcome in Patients with Acute Decompensated Heart Failure with Preserved Ejection Fraction
Background: Although insulin resistance (IR) is associated with a higher risk of incident heart failure (HF), it is not fully understood whether IR could affect clinical outcomes in patients with established HF. We investigated the relationship between the triglyceride-glucose (TyG) index, a simple surrogate marker for IR, and clinical outcomes in patients with HF with preserved ejection fraction (HFpEF). Methods: This retrospective analysis from the PURSUIT-HFpEF registry included 917 patients hospitalized for decompensated HFpEF. The TyG index was calculated at discharge as ln(triglyceride [mg/dL] × fasting blood glucose [mg/dL]/2). The primary outcomes were all-cause death and major adverse cardiovascular events (MACEs; a composite of all-cause death, heart failure hospitalization, and stroke). Results: The median age of patients was 83 years, 44.7% was male, and 39.2% had diabetes. The median BMI was 21.5 kg/m², with 20.9% having BMI <18.5 kg/m ². During a median follow-up of 387 days, 168 deaths and 343 MACEs occurred. A stepwise Cox hazard model revealed that higher TyG index was independently associated with lower risk of all-cause death (HR 0.53, 95% CI 0.38-0.75) and MACEs (HR 0.77, 95% CI 0.61-0.97). When patients were divided into quartiles based on TyG index, the incidences of both outcomes were significantly lower in higher TyG quartiles (all-cause death; p=0.0003, MACEs; p=0.007 by log-rank). Conclusions: In this predominantly elderly, low BMI cohort with established HFpEF, higher TyG index was paradoxically associated with better clinical outcomes. These findings imply a complex relationship between IR and HFpEF outcomes. Clinical Perspective: 1) What is new?: The triglyceride-glucose (TyG) index is a novel, easily calculated surrogate marker for insulin resistance (IR) using only serum triglyceride and fasting blood glucose levels. A higher TyG index, reflecting greater IR, was paradoxically associated with a lower incidence of all-cause mortality and major adverse cardiovascular events in patients hospitalized with heart failure with preserved ejection fraction (HFpEF) over approximately one year of follow-up. This association remained consistent across various subgroups stratified by age, sex, BMI, diabetes status, and other risk factors. 2) What are the clinical implications?: A paradoxical relationship between IR and clinical outcomes may exist in predominantly older, low-BMI Japanese patients with established HFpEF. The prognostic impact of IR in established heart failure appears complex and may vary depending on patient characteristics.
Open AccessAssociation between Triglyceride-Glucose Index and Clinical Outcome in Patients with Acute Decompensated Heart Failure with Preserved Ejection Fraction
Background: Although insulin resistance (IR) is associated with a higher risk of incident heart failure (HF), it is not fully understood whether IR could affect clinical outcomes in patients with established HF. We investigated the relationship between the triglyceride-glucose (TyG) index, a simple surrogate marker for IR, and clinical outcomes in patients with HF with preserved ejection fraction (HFpEF). Methods: This retrospective analysis from the PURSUIT-HFpEF registry included 917 patients hospitalized for decompensated HFpEF. The TyG index was calculated at discharge as ln(triglyceride [mg/dL] × fasting blood glucose [mg/dL]/2). The primary outcomes were all-cause death and major adverse cardiovascular events (MACEs; a composite of all-cause death, heart failure hospitalization, and stroke). Results: The median age of patients was 83 years, 44.7% was male, and 39.2% had diabetes. The median BMI was 21.5 kg/m², with 20.9% having BMI <18.5 kg/m ². During a median follow-up of 387 days, 168 deaths and 343 MACEs occurred. A stepwise Cox hazard model revealed that higher TyG index was independently associated with lower risk of all-cause death (HR 0.53, 95% CI 0.38-0.75) and MACEs (HR 0.77, 95% CI 0.61-0.97). When patients were divided into quartiles based on TyG index, the incidences of both outcomes were significantly lower in higher TyG quartiles (all-cause death; p=0.0003, MACEs; p=0.007 by log-rank). Conclusions: In this predominantly elderly, low BMI cohort with established HFpEF, higher TyG index was paradoxically associated with better clinical outcomes. These findings imply a complex relationship between IR and HFpEF outcomes. Clinical Perspective: 1) What is new?: The triglyceride-glucose (TyG) index is a novel, easily calculated surrogate marker for insulin resistance (IR) using only serum triglyceride and fasting blood glucose levels. A higher TyG index, reflecting greater IR, was paradoxically associated with a lower incidence of all-cause mortality and major adverse cardiovascular events in patients hospitalized with heart failure with preserved ejection fraction (HFpEF) over approximately one year of follow-up. This association remained consistent across various subgroups stratified by age, sex, BMI, diabetes status, and other risk factors. 2) What are the clinical implications?: A paradoxical relationship between IR and clinical outcomes may exist in predominantly older, low-BMI Japanese patients with established HFpEF. The prognostic impact of IR in established heart failure appears complex and may vary depending on patient characteristics.
- Open Access
- 12 March 2025
- Published by Elsevier in JACC: Heart Failure
- Vol. 13 (6) , 1014-1026
Validation of Guideline Recommendation on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy
- 12 March 2025
- Published by Elsevier in JACC: Heart Failure
- Vol. 13 (6) , 1014-1026
Open AccessValidation of Guideline Recommendation on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy
- Open Access
- 1 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (5)
Impact of left atrial appendage flow velocity on thrombus resolution and clinical outcomes in patients with atrial fibrillation and silent left atrial thrombi: insights from the LAT study
Aims: Blood stasis is crucial in developing left atrial (LA) thrombi. LA appendage peak flow velocity (LAAFV) is a quantitative parameter for estimating thromboembolic risk. However, its impact on LA thrombus resolution and clinical outcomes remains unclear. Methods and results: The LAT study was a multicentre observational study investigating patients with atrial fibrillation (AF) and silent LA thrombi detected by transoesophageal echocardiography (TEE). Among 17 436 TEE procedures for patients with AF, 297 patients (1.7%) had silent LA thrombi. Excluding patients without follow-up examinations, we enrolled 169 whose baseline LAAFV was available. Oral anticoagulation use increased from 85.7% at baseline to 97.0% at the final follow-up (P < 0.001). During 1 year, LA thrombus resolution was confirmed in 130 (76.9%) patients within 76 (34–138) days. Conversely, 26 had residual LA thrombi, 8 had thromboembolisms, and 5 required surgical removal. These patients with failed thrombus resolution had lower baseline LAAFV than those with successful resolution (18.0 [15.8–22.0] vs. 22.2 [17.0–35.0], P = 0.003). Despite limited predictive power (area under the curve, 0.659; P = 0.001), LAAFV ≤ 20.0 cm/s (best cut-off) significantly predicted failed LA thrombus resolution, even after adjusting for potential confounders (odds ratio, 2.72; 95% confidence interval, 1.22–6.09; P = 0.015). The incidence of adverse outcomes including ischaemic stroke/systemic embolism, major bleeding, or all-cause death was significantly higher in patients with reduced LAAFV than in those with preserved LAAFV (28.4% vs. 11.6%, log-rank P = 0.005). Conclusion: Failed LA thrombus resolution was not rare in patients with AF and silent LA thrombi. Reduced LAAFV was associated with failed LA thrombus resolution and adverse clinical outcomes.
- 1 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (5)
Open AccessImpact of left atrial appendage flow velocity on thrombus resolution and clinical outcomes in patients with atrial fibrillation and silent left atrial thrombi: insights from the LAT study
Aims: Blood stasis is crucial in developing left atrial (LA) thrombi. LA appendage peak flow velocity (LAAFV) is a quantitative parameter for estimating thromboembolic risk. However, its impact on LA thrombus resolution and clinical outcomes remains unclear. Methods and results: The LAT study was a multicentre observational study investigating patients with atrial fibrillation (AF) and silent LA thrombi detected by transoesophageal echocardiography (TEE). Among 17 436 TEE procedures for patients with AF, 297 patients (1.7%) had silent LA thrombi. Excluding patients without follow-up examinations, we enrolled 169 whose baseline LAAFV was available. Oral anticoagulation use increased from 85.7% at baseline to 97.0% at the final follow-up (P < 0.001). During 1 year, LA thrombus resolution was confirmed in 130 (76.9%) patients within 76 (34–138) days. Conversely, 26 had residual LA thrombi, 8 had thromboembolisms, and 5 required surgical removal. These patients with failed thrombus resolution had lower baseline LAAFV than those with successful resolution (18.0 [15.8–22.0] vs. 22.2 [17.0–35.0], P = 0.003). Despite limited predictive power (area under the curve, 0.659; P = 0.001), LAAFV ≤ 20.0 cm/s (best cut-off) significantly predicted failed LA thrombus resolution, even after adjusting for potential confounders (odds ratio, 2.72; 95% confidence interval, 1.22–6.09; P = 0.015). The incidence of adverse outcomes including ischaemic stroke/systemic embolism, major bleeding, or all-cause death was significantly higher in patients with reduced LAAFV than in those with preserved LAAFV (28.4% vs. 11.6%, log-rank P = 0.005). Conclusion: Failed LA thrombus resolution was not rare in patients with AF and silent LA thrombi. Reduced LAAFV was associated with failed LA thrombus resolution and adverse clinical outcomes.